SIRPant Immunotherapeutics Appoints Jelle Kijlstra, MD, MBA as Chief Medical Officer

HUMMELSTOWN, Pa.–(BUSINESS WIRE)–SIRPant Immunotherapeutics Inc, a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Jelle Kijlstra, MD, MBA as its new Chief Medical Officer. Dr. Kijlstra brings more than 30 years of experience as a clinician-scientist and drug developer to SIRPant Immunotherapeutics where he will be respo

Recent Articles